pdufa.bio
Home › Decisions › MRK 2026-04-21

MRK FDA decision — Apr 21, 2026

✓ APPROVED

Merck & Company Inc. — IDVYNSO (doravirine/islatravir) · HIV-1 Infection.

Run-up into the decision (T-120 → T+5)

PDUFA 4/21/26$123.93$82.4911/4/25
Daily close, T-120 (11/4/25) through T+5. Run-up high $123.93 on 2/25/26, low $82.49 on 11/11/25 (T-120 to T-1). FDA decision 4/21/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-04-21
OutcomeApproved
Drug / candidateIDVYNSO (doravirine/islatravir)
CompanyMerck & Company Inc.
120-day run-up (T-120→T-1)+33.1%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio